Lilly and Resilience: $750M GLP-1 capacity

On 31 July 2026 contract manufacturer Resilience and Eli Lilly announced a combined $750 million investment to expand sterile injectable manufacturing in the Cincinnati region^[1]. The expansion targets tirzepatide and other GLP-1 class injectables. If you track GLP-1 supply, shortages, or the question of whether branded capacity can keep pace with demand, here is what the deal covers and what it does not.

What the investment covers

Resilience operates two facilities in the Blue Ash area of Cincinnati totalling nearly one million square feet^[1]. The $750 million will fund additional capacity inside those buildings, with site preparation already underway as of the announcement date and full production operations expected to start in early 2027. The work centres on sterile injectable fill-finish and device assembly, specifically the KwikPen autoinjector that Lilly uses for Mounjaro and Zepbound.

The two companies have worked together since 2023. In that time Resilience has produced more than 150 million doses of Lilly GLP-1 medicines in vial and pre-filled syringe formats for US patients^[1]. The new capital extends and deepens that relationship. Mounjaro (type-2 diabetes) and Zepbound (weight management) are both produced through this partnership.

Jobs and scale

The expansion creates at least 400 new positions, bringing Resilience's total Cincinnati headcount above 1,400^[1]. All of the new roles are dedicated to GLP-1 injectable production. That headcount concentration at a single contract manufacturer reflects how much of Lilly's physical output now runs through third-party fill-finish rather than wholly owned Lilly plants.

Contract manufacturing at this scale is common in pharmaceutical supply chains, but the size of the individual deal is unusual. Most fill-finish contracts are smaller and shorter-term. A $750 million commitment spread across a partnership that already spans three years signals Lilly is treating Resilience as structural infrastructure for the tirzepatide programme rather than as overflow capacity.

Where this fits in Lilly's wider manufacturing push

The Cincinnati deal is one piece of a larger US manufacturing expansion. Since September 2025 Lilly has committed more than $16 billion to domestic production, including new facilities in Houston, Huntsville (Alabama), and Pennsylvania, plus an additional $4.5 billion at existing Lebanon, Indiana sites^[1]. The company is betting that GLP-1 demand will sustain a manufacturing base that, as recently as 2022, did not need to exist at this scale.

Morgan Stanley has projected the global GLP-1 market could exceed $190 billion by 2035^[1]. Whether that projection lands close to reality or not, manufacturers are acting as if supply constraints are a long-term business risk. Semaglutide faced similar capacity constraints before Novo Nordisk expanded its own fill-finish operations. That pattern is repeating now with tirzepatide at larger scale.

What this means for supply and availability

Tirzepatide (Mounjaro for type-2 diabetes, Zepbound for weight management) was listed on the FDA drug shortage database from 2022 through early 2025, when the agency removed it after Lilly increased production^[2]. The shortage drove a period of compounding pharmacy activity: third-party pharmacies produced tirzepatide under FDA shortage provisions, and once the shortage resolved, the agency sent guidance to compounders about continued access rules.

The new Cincinnati capacity is designed to prevent a return to shortage-level constraints as prescribing expands. The FDA's position after the 2025 resolution was that national tirzepatide supply had stabilised^[2]; the Resilience investment is the industrial infrastructure meant to sustain that for the next several years of demand growth.

What this does not change

More US fill-finish capacity does not automatically lower the price of branded tirzepatide or improve insurance coverage. The causes of access barriers are pricing and formulary decisions, not manufacturing throughput. Patients who cannot currently afford or obtain Mounjaro or Zepbound through their insurance are not directly helped by the Cincinnati expansion.

Nor does it affect the regulatory status of compounded tirzepatide. The FDA's rules on compounding are tied to the shortage designation, not to manufacturing volume at any particular plant. For a current picture of how tirzepatide is regulated in different countries, see the tirzepatide regulation pages.

Why contract manufacturing matters for this class

GLP-1 receptor agonists are biologics produced by fermentation and then processed through careful sterile fill-finish steps. The KwikPen assembly that Resilience handles is the final stage of that process: filling the drug into a device that patients inject once a week^[3]. Quality failures at this stage, contamination, misfills, device defects, are the proximate causes of most injectable drug recalls. Resilience operates under FDA oversight as a contract manufacturer and its Cincinnati plants are subject to the same cGMP inspections as any drug facility.

The capacity added by the $750 million investment gives Lilly a larger buffer between prescription demand and fill-finish throughput. That buffer matters because tirzepatide prescribing is still growing: the ACP placed it among first-line obesity treatments in June 2026^[3] and label expansions (paediatric type-2 diabetes in the EU, obstructive sleep apnea in the US) continue to widen the eligible population.

What to watch next

The Cincinnati expansion is scheduled to reach full capacity in early 2027. The questions that will determine whether it actually closes supply constraints are: whether demand growth continues at its current pace, whether any cGMP inspection findings affect the facilities before or after launch, and whether Lilly's wholly-owned plants in Indiana and elsewhere hit their production targets on schedule. Capacity announcements and production reality sometimes diverge. The 150 million doses already produced by Resilience since 2023 is the more concrete data point. For current regulatory and availability detail by country, see the tirzepatide regulation pages and the US regulation hub.